LUNG - Pulmonx Corp logo

Pulmonx Corp

LUNG

Pulmonx Corporation develops minimally invasive treatments for severe emphysema, primarily through its Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System. Its LungTraX Platform provides cloud-based analysis for enhanced patient assessment and treatment.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago →$46today

Score Overview

1 Year
Score
Net Growth10.90%
Net TrendGrew
Net Income Consistency—
Rev Growth-3.38%
Rev TrendShrank
Revenue Consistency—
5 Years
Score5.6
Net Growth1.12%
Net Trend60%
Net Income Consistency—
Rev Growth80.61%
Rev Trend80%
Revenue Consistency—
All Time
Score
Net Growth-49.28%
Net Trend50%
Net Income Consistency
Rev Growth167.14%
Rev Trend83%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Pulmonx Corp has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. LUNG does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 1.83—
1 Year2025-10-23
$ 1.5915.09%
5 Years2021-10-22
$ 39.54-95.37%
All Time2020-10-01
$ 39.31-95.34%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 87M-$ 48M$ 55M
2025$ 90M-$ 54M$ 70M
2024$ 83M-$ 56M$ 101M
2023$ 68M-$ 60M$ 117M
2022$ 53M-$ 58M$ 141M
2021$ 48M-$ 48M$ 180M
IPO2020$ 32M-$ 32M$ 231M
LUNG - Pulmonx Corp logo

Pulmonx Corp fundamental performance

Between 2020 and 2025, revenue grew from $ 32M to $ 90M and net income went from -$ 32M to -$ 54M. Revenue increased in 4 of those 5 years; net income in 3.

Pulmonx Corp currently holds a 5-year HDB Score of 5.6 out of 10. How the HDB Score is calculated.

Membership

Explore LUNG with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies